Medtronicbeat Q4收入估计数,提出了2026年的指导意见,但投资者的担忧在一位顶尖执行官出售了数百万股后有所上升。 Medtronic beat Q4 earnings estimates, raised 2026 guidance, but investor concern rose after a top executive sold millions in shares.

Medtronic报告说,2026年2月17日,Q4收入强劲,为1.36 EPS和90.2亿美元的收入、打人估计数,提高了2026年全年EPS指南。 Medtronic reported strong Q4 earnings on February 17, 2026, with $1.36 EPS and $9.02 billion in revenue, beating estimates, and raised its 2026 full-year EPS guidance. 2月19日, 执行副总裁哈里·斯基普·基尔(Harry Skipp Kiil)出售了52 524股股票, Executive Vice President Harry Skip Kiil sold 52,524 shares on February 19, reducing his stake by 61.58% and netting about $5.13 million, prompting investor caution. 该公司保持稳固的财政状况,债务与股权比率为0.57和2.9%,红利收益率为2.9%。 The company maintains a solid financial profile with a debt-to-equity ratio of 0.57 and a 2.9% dividend yield. 分析师将该股评为“中度买入”，平均目标为110.84美元。 Analysts rate the stock a "Moderate Buy" with a $110.84 average target.